Fintel reports that on April 17, 2023,
Piper Sandler
maintained
coverage of Codexis (NASDAQ:CDXS) with
a Overweight recommendation.
Analyst Price Forecast Suggests 201.90% Upside
As of April 6, 2023,
the average one-year price target for Codexis is $13.13.
The forecasts range from a low of $7.07 to a high of $22.05.
The average price target represents an increase of 201.90% from its latest reported closing price of $4.35.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Codexis
is $94MM, a decrease of 32.31%.
The projected annual non-GAAP EPS
is -$1.07.
What are Other Shareholders Doing?
VRTTX – Vanguard Russell 3000 Index Fund Institutional Shares
holds 5K shares
representing 0.01% ownership of the company.
No change in the last quarter.
Qube Research & Technologies
holds 131K shares
representing 0.20% ownership of the company.
In it’s prior filing, the firm reported owning 35K shares, representing
an increase
of 73.29%.
The firm
increased
its portfolio allocation in CDXS by 158.19% over the last quarter.
SUNAMERICA SERIES TRUST – SA Small Cap Index Portfolio Class 1
holds 7K shares
representing 0.01% ownership of the company.
In it’s prior filing, the firm reported owning 7K shares, representing
a decrease
of 0.36%.
The firm
increased
its portfolio allocation in CDXS by 4.24% over the last quarter.
Dynamic Technology Lab Private
holds 77K shares
representing 0.12% ownership of the company.
In it’s prior filing, the firm reported owning 152K shares, representing
a decrease
of 98.72%.
The firm
decreased
its portfolio allocation in CDXS by 60.75% over the last quarter.
NATIONWIDE VARIABLE INSURANCE TRUST – NVIT GS Small Cap Equity Insights Fund Class Y
holds 39K shares
representing 0.06% ownership of the company.
In it’s prior filing, the firm reported owning 46K shares, representing
a decrease
of 17.63%.
The firm
decreased
its portfolio allocation in CDXS by 37.79% over the last quarter.
What is the Fund Sentiment?
There are 353 funds or institutions reporting positions in Codexis.
This is a decrease
of
20
owner(s) or 5.36% in the last quarter.
Average portfolio weight of all funds dedicated to CDXS is 0.09%,
a decrease
of 23.00%.
Total shares owned by institutions decreased
in the last three months by 3.05% to 74,447K shares.
The put/call ratio of CDXS is 0.29, indicating a
bullish
outlook.
Codexis Background Information
(This description is provided by the company.)
Codexis is a leading enzyme engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
See all Codexis regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
